Methods and nucleic acid molecules for aav vector selection
US-2024417717-A1 · Dec 19, 2024 · US
Immunogens comprising human immunodeficiency virus V1/V2 polypeptides
US9988424B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9988424-B2 |
| Application number | US-201214363131-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 5, 2012 |
| Priority date | Dec 5, 2011 |
| Publication date | Jun 5, 2018 |
| Grant date | Jun 5, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention is generally directed to V1V2 immunogens.
First claim
Opening claim text (preview).
What is claimed is: 1. A V1V2 polypeptide, wherein the polypeptide is AE.A244 V1/V2 (SEQ ID NO: 184), AE.A244 V1/V2tag (SEQ ID NO: 196), A.Q23V1/V2 (SEQ ID NO: 183), or A.Q23V1/V2tag (SEQ ID NO: 195). 2. A composition comprising any one of the polypeptides of claim 1 and a carrier. 3. The composition according to claim 2 further comprising an adjuvant. 4. A V1V2 polypeptide, wherein the polypeptide consists essentially of peptide AE.A244 V1/V2 (SEQ ID NO: 184), AE.A244 V1/V2tag (SEQ ID NO: 196), A.Q23V1/V2 (SEQ ID NO: 183), or A.Q23V1/V2tag (SEQ ID NO: 195). 5. The composition of claim 2 , wherein the polypeptide is AE.A244 V1/V2 (SEQ ID NO: 184). 6. The composition of claim 2 , wherein the polypeptide is AE.A244 V1/V2tag (SEQ ID NO: 196). 7. The composition of claim 2 , wherein the polypeptide is A.Q23V1/V2 (SEQ ID NO: 183). 8. The composition of claim 2 , wherein the polypeptide is A.Q23V1/V2tag (SEQ ID NO: 195). 9. The composition of claim 5 further comprising an adjuvant. 10. The composition according to claim 6 further comprising an adjuvant. 11. The composition according to claim 7 further comprising an adjuvant. 12. The composition according to claim 8 further comprising an adjuvant. 13. A method of inducing antibodies to the V1V2 region of HIV-1 env gp120 in a subject comprising administering to said subject the composition of claim 2 . 14. The method according to claim 13 wherein said subject is a human. 15. The method according to claim 13 further comprising administering an adjuvant. 16. The method according to claim 13 , wherein the composition is administered as prime. 17. A method of inducing antibodies to the V1V2 region of HIV-1 env gp120 in a subject comprising administering to said subject a composition comprising the polypeptide of claim 4 and a carrier. 18. The method according to claim 17 further comprising administering an adjuvant. 19. The method according to claim 17 , wherein the composition is administered as prime. 20. The method according to claim 17 , wherein the polypeptide consists essentially of peptide AE.A244 V1/V2 (SEQ ID NO: 184) or AE.A244 V1/V2tag (SEQ ID NO: 196).
Assignees
Inventors
Classifications
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
Fab or Fab' · CPC title
viral genome or elements thereof as genetic vector · CPC title
Viral antigens · CPC title
for HIV · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9988424B2 cover?
- The invention is generally directed to V1V2 immunogens.
- Who is the assignee on this patent?
- Univ Duke, Us Army, Univ New York, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07K14/005. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 05 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).